All News
Filter News
Found 138 articles
-
Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
10/23/2022
Phathom Pharmaceuticals, Inc. announced that detailed results from an investigational Phase 2 study evaluating the efficacy of vonoprazan in non-erosive gastroesophageal reflux disease and other data will be presented at the American College of Gastroenterology 2022 Annual Scientific Meeting, being held October 21-26 in Charlotte, NC.
-
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
10/18/2022
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced today the company will present new data and research at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, being held October 21-26 in Charlotte, NC.
-
Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan
10/10/2022
Evonik has entered into a long-term supply agreement with Phathom Pharmaceuticals, a U.S. biopharmaceutical company focused on developing and commercializing new treatments for gastric acid-related diseases.
-
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
9/26/2022
Phathom Pharmaceuticals, Inc. today announced the appointment of James “Jamie” Topper, M.D., Ph.D., to its Board of Directors.
-
Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/7/2022
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference.
-
Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates
8/2/2022
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the second quarter of 2022 and provided recent business updates.
-
Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
6/1/2022
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:30 p.m. ET.
-
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
5/25/2022
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for vonoprazan.
-
Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022
5/24/2022
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that results from multiple studies evaluating the efficacy of vonoprazan were presented at Digestive Disease Week® (DDW) 2022, being held May 21-24 in person in San Diego, CA and virtually.
-
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
5/17/2022
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), an innovative biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the company will present findings from multiple studies at Digestive Disease Week® (DDW) 2022, being held May 21-24 in person in San Diego, CA and virtually.
-
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
5/10/2022
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2022 and provided updates on recent clinical, regulatory, and business progress.
-
The FDA has approved two of Phathom Pharmaceuticals' products for bacterial illnesses in adults: Voquezna Triple Pak and Voquezna Dual Pak.
-
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
5/4/2022
Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced a revenue interest financing of up to $260 million in non-dilutive capital.
-
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
5/3/2022
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) approved both VOQUEZNA™ TRIPLE PAK™ (vonoprazan tablets.
-
As May gets off to a slow start for the FDA calendar, a few companies have important target action dates.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
4/26/2022
Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced the appointment of Frank Karbe to its Board of Directors.
-
Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
4/1/2022
Phathom Pharmaceuticals, Inc. announced today that members of the management team will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 9:30 a.m. ET.
-
Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
3/22/2022
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer.
-
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
3/14/2022
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), announced today that it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of vonoprazan as a treatment for adults for the healing of all grades of erosive esophagitis (EE) and relief of heartburn, and maintenance of healing of all grades of EE and relief of heartburn.